SCOPE
Coenzyme Q10 (CoQ10) has become a popular nutritional supplement due to its wide range of beneficial biological effects. Previous meta-analyses showed that the attenuation of CoQ10 on inflammatory biomarkers remained controversial. This meta-analysis aimed to assess the efficacy and optimal dose of CoQ10 supplementation on inflammatory indicators in the general population.
METHODS AND RESULTS
Databases are searched up to December 2022 resulting in 6713 articles, of which 31 were retrieved for full-text assessment and included 1517 subjects. Double-blind randomized controlled trials (RCTs) of CoQ10 supplementation were eligible if they contain C reactive protein (CRP), interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α). CoQ10 supplementation could significantly reduce the levels of circulating CRP (SMD: -0.40, 95% CI: [-0.67 to -0.13], p = 0.003), IL-6 (SMD: -0.67, 95% CI: [-1.01 to -0.33], p < 0.001) and TNF-α (SMD: -1.06, 95% CI: [-1.59 to -0.52], p < 0.001) and increase the concentration of circulating CoQ10.
CONCLUSION
This meta-analysis provides evidence for CoQ10 supplementation to reduce the level of inflammatory mediators in the general population and proposes that daily supplementation of 300-400 mg CoQ10 showed superior inhibition of inflammatory factors. This article is protected by copyright. All rights reserved.